Immunology and Microbiology
Severe Acute Respiratory Syndrome Coronavirus 2
100%
Influenza
82%
B Cell
51%
Influenza Virus
49%
Spike
43%
Monoclonal Antibody
40%
Antibody Response
39%
Virus
38%
Memory B Cell
35%
Germinal Center
35%
Viral Disease
35%
Epitope
32%
Neutralizing Antibody
29%
Hemagglutinin
28%
COVID-19
25%
Influenza A Virus (H1N1)
25%
Influenza Vaccine
19%
Influenzavirus A
18%
Lymph Node
17%
Immunity
17%
Neutralization
16%
Plasmablast
16%
Influenza A Virus (H5N1)
15%
T Cell
14%
Omicron Coronavirus Variant
13%
Blood Plasma
13%
Immunogenicity
13%
Receptor Binding
12%
Immune Response
11%
Maturation
11%
Human Monoclonal Antibody
10%
Humoral Immunity
10%
Follicular B Helper T Cells
9%
Cytotoxic T-Cell
9%
Glycoprotein
9%
Infectious Agent
9%
Titer
9%
Viral Load
8%
Immunoglobulin Producing Cell
8%
Antigen Specificity
8%
T-Helper Cell
8%
Inflammatory Disorder
8%
Intravenous Immunoglobulin
8%
Polyclonal Antibody
8%
Naive B Cell
8%
Immunosuppression
8%
Antibody Blood Level
7%
Vaccination
7%
Cytokine
7%
Antigenicity
7%
Keyphrases
COVID-19
81%
Vaccination
54%
Monoclonal Antibody
46%
Influenza Virus
45%
Influenza
39%
Memory B Cells
37%
Antibody Response
35%
Neuraminidase
31%
B Cell Response
31%
Virus
28%
B Cells
26%
Germinal Center
24%
Vaccine Response
23%
MRNA Vaccine
22%
Hemagglutinin
21%
Influenza-like Illness
20%
Influenza Vaccine
20%
Epitope
19%
Neutralizing Antibodies
19%
Plasmablast
19%
Influenza Vaccination
19%
Broadly Protective
19%
Germinal Center Reaction
19%
Germinal Center B Cells
18%
Severe Acute Respiratory Syndrome Coronavirus 2 Infection
17%
H5N1
16%
Human Antibody
13%
Pre-existing Immunity
13%
Conserved Epitopes
13%
Antibody Targeting
13%
Immunization
13%
Lymph Node
12%
Virus Infection
12%
Immune Response
11%
Cell Response
11%
T Follicular Helper Cells
10%
Active Sites
10%
SARS-CoV-2 Variants
10%
Spike Protein
10%
Receptor-binding Domain
10%
Somatic Hypermutation
10%
Protective Antibodies
10%
SARS-CoV-2 Infection
10%
Bronchoalveolar Lavage
10%
Neutralizing Activity
9%
Naïve B Cells
9%
T Cells
9%
Antigen-specific
9%
Chronic Inflammatory Diseases
8%
Vaccine Development
8%